TRENTON, N.J. – New studies show GlaxoSmithKline PLC’s vaccine Cervarix blocks the virus that causes cervical cancer, but if it wins approval for U.S. sales, it will face an uphill battle against Gardasil, which has owned the market here for three years.
Cervarix, Glaxo’s vaccine against human papilloma virus or HPV, already is approved in more than 90 other countries but has been held up by delays in the United States. Several years ago, the British drugmaker was in a neck-and-neck race with rival Merck & Co., Gardasil’s maker, to be first on the U.S. market, but it lost when Gardasil got approved in June 2006.
______
To read the rest of this article, subscribe to our digital or paper edition. For previous editions, contact us for details.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
